The overarching aim of the Microphysiological Tissue Models group is to increase the translatability of preclinical drug discovery and development. To achieve this goal, we develop advanced organotypic and microphysiological models that closely recapitulate the molecular and cellular phenotypes and functions of human tissues in vivo. Following careful benchmarking and validation, we utilize these tools to discover relevant disease mechanisms and identify novel drug targets for inflammatory conditions, complex metabolic diseases and cancer.